DFV890

DFV890 is an orally administered, potent, and selective small molecule inhibitor of NLRP3 (NOD-like receptor family pyrin domain containing 3), the sensor component of the NLRP3 inflammasome. By directly binding to NLRP3 and locking it in an inactive conformation, DFV890 prevents assembly of the inflammasome complex in response to sterile danger signals. This inhibition blocks activation of caspase-1 and subsequent maturation and release of pro-inflammatory cytokines such as IL-1β and IL-18, as well as pyroptotic cell death[1][2][5][6]. The drug was originally developed by IFM Tre and later acquired by Novartis[1]. It is under investigation for several inflammatory conditions including COVID-19 pneumonia, coronary heart disease (especially with elevated hsCRP or clonal hematopoiesis), symptomatic knee osteoarthritis, myeloid diseases (such as lower-risk myelodysplastic syndromes and chronic myelomonocytic leukemia), familial cold autoinflammatory syndrome (FCAS), among others[1][4].

Other names

IFM-NLRP3IFM-NLRP-3IFM-NLRP 3NLRP3 inhibitor programNLRP-3 inhibitor programNLRP 3 inhibitor program